CLOUDR(09955) plans to issue convertible bonds with a total principal amount of $4.5 million.

CLOUDR (09955) announced that on March 10, 2025, the company entered into a subscription agreement with the subscribers and the exclusive placing agent to issue convertible bonds with a principal amount of $4.5 million to the subscribers. The convertible bonds are convertible at an initial conversion price of HK$2.10 per share (adjustable) and, upon full conversion, will result in the issuance of a total of 16.645 million shares, representing approximately 2.58% of the company's existing issued share capital and approximately 2.51% of the company's issued share capital after the issuance of conversion shares. The conversion shares will be allotted and issued under the general mandate. The Group intends to utilize the proceeds from the issuance of convertible bonds as follows: approximately $2.25 million for the development of the Group's day-to-day operations, including the development of the Patient-to-Manufacturer (P2M) pipeline and expansion of the pharmacy SaaS (Software as a Service); and approximately $2.25 million for general working capital.